GlassScriptPhysician profile
Mary A Crow
NPI 1114244613
$925.20
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $95.18 · 2022: $25.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $144.70 | 2019-2020 | |
| Ucb, INC. | $114.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $86.02 | 2019 | |
| Lilly USA, LLC | $74.97 | 2019-2020 | |
| Pfizer INC. | $69.42 | 2019 | |
| Abbvie INC. | $58.30 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $58.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.63 | 2019 | |
| Amarin Pharma, INC. | $41.47 | 2019 | |
| Merck Sharp & Dohme LLC | $38.61 | 2019 | |
| Amgen INC. | $33.30 | 2019 | |
| Shire North American Group INC | $32.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.58 | 2019 | |
| Gilead Sciences, INC. | $26.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.47 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.09 | 2019 | |
| Horizon Therapeutics Plc | $10.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Crow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.